Drugs / Intrathecal autologous stem cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT01933321 | Sep 2012 → Jan 2014 | amyotrophic lateral sclerosis | Hospital Universitario Dr. Jose E. Gonzalez | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Intrathecal autologous stem cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01933321 ↗ |
| Modality | Cell therapy | “Autologous cell therapy in patients with ALS can stimulate neuroplasticity, modifying the neurodegenerative process and stops the clinical progression of disease.” NCT01933321 ↗ |
| Route | Intrathecal | “Intrathecal stem cells will be administered to patients that fulfill the inclusion criteria.” NCT01933321 ↗ |